|Articles|May 22, 2015
SVR Achieved With 8-Week Course in Coinfected Hepatitis C Patients
Encouraging results with a shorter course of hepatitis C treatment were presented at the Digestive Disease Week meeting. Patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment, achieved a sustained response at 12 weeks.
Advertisement
Results, presented at the Digestive Disease Week meeting, from HIV-coinfected hepatitis C virus (HCV) patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment., were encouraging The data showed that once-daily daclatasvir combined with sofosbuvir, administered for 8 weeks, achieved a sustained virologic response in more than 75% of patients, 12 weeks after finishing the course.
While the treatment was well-tolerated overall, post-treatment hepatitis C virus relapse occurred in 1% to 2% of patients in the 12-week treatment groups and in about 25% in the 8-week group.
Read the complete article on MedPage Today:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
2
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
3
Intermountain Spans Time Zones, Cultures to Bring Oncology Care to Alaska
4
NIH F32 Grants Boost Early-Career Researchers’ Success
5
